Sangamo Therapeutics Revenue vs. Price To Earning

SGMO Stock  USD 0.92  0.02  2.13%   
Based on Sangamo Therapeutics' profitability indicators, Sangamo Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in November. Profitability indicators assess Sangamo Therapeutics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2000-03-31
Previous Quarter
481 K
Current Value
356 K
Quarterly Volatility
18.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of the 20th of October 2024, Price To Sales Ratio is likely to drop to 0.51. In addition to that, Days Sales Outstanding is likely to drop to 2.61. At this time, Sangamo Therapeutics' Non Operating Income Net Other is very stable compared to the past year. As of the 20th of October 2024, Change To Netincome is likely to grow to about 38.2 M, though Accumulated Other Comprehensive Income is likely to grow to (4.4 M).
For Sangamo Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sangamo Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sangamo Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sangamo Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sangamo Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.38)
Revenue Per Share
0.066
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.58)
Return On Equity
(1.94)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sangamo Therapeutics Price To Earning vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sangamo Therapeutics's current stock value. Our valuation model uses many indicators to compare Sangamo Therapeutics value to that of its competitors to determine the firm's financial worth.
Sangamo Therapeutics is rated third in revenue category among its peers. It also is rated third in price to earning category among its peers . At this time, Sangamo Therapeutics' Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sangamo Therapeutics' earnings, one of the primary drivers of an investment's value.

Sangamo Revenue vs. Competition

Sangamo Therapeutics is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 2.44 Billion. Sangamo Therapeutics holds roughly 176.23 Million in revenue claiming about 7% of equities under Health Care industry.

Sangamo Price To Earning vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Sangamo Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
176.23 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Sangamo Therapeutics

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
(15.31) X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Sangamo Price To Earning Comparison

Sangamo Therapeutics is currently under evaluation in price to earning category among its peers.

Sangamo Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sangamo Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sangamo Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Sangamo Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Sangamo Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4.6 M-4.4 M
Operating Income-114.3 M-108.6 M
Net Loss-257.8 M-244.9 M
Income Tax Expense-5.1 M-4.8 M
Income Before Tax-262.9 M-249.8 M
Total Other Income Expense Net-148.6 M-141.2 M
Net Loss-249.5 M-237 M
Non Operating Income Net Other10.8 M11.4 M
Net Loss-173.1 M-164.4 M
Interest Income13.3 M7.1 M
Net Interest Income13.3 M7.9 M
Change To Netincome36.4 M38.2 M
Net Loss(1.48)(1.55)
Income Quality 0.87  0.92 
Net Income Per E B T 0.98  0.77 

Sangamo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sangamo Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sangamo Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sangamo Therapeutics' important profitability drivers and their relationship over time.

Use Sangamo Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Sangamo Therapeutics Pair Trading

Sangamo Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sangamo Therapeutics position

In addition to having Sangamo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Industrials ETFs Thematic Idea Now

Industrials ETFs
Industrials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out World Market Map.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
To fully project Sangamo Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sangamo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sangamo Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Sangamo Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sangamo Therapeutics investors may work on each financial statement separately, they are all related. The changes in Sangamo Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sangamo Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.